192 related articles for article (PubMed ID: 32793489)
1. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
3. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
6. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
10. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.
Matsuda T; Takeuchi H; Sakurai T; Mayanagi S; Booka E; Fujita T; Higuchi H; Taguchi J; Hamamoto Y; Takaishi H; Kawakubo H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Oncol Lett; 2018 Jul; 16(1):1348-1356. PubMed ID: 29963201
[TBL] [Abstract][Full Text] [Related]
12. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
13. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
14. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
15. Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review.
De Martino L; Picariello S; Russo C; Errico ME; Spennato P; Papa MR; Normanno N; Scimone G; Colafati GS; Cacchione A; Mastronuzzi A; Massimino M; Cinalli G; Quaglietta L
Front Mol Neurosci; 2023; 16():1152430. PubMed ID: 37547920
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
[TBL] [Abstract][Full Text] [Related]
18. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
19. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
[TBL] [Abstract][Full Text] [Related]
20. Pediatric H3K27M‑mutant diffuse midline glioma with vertebral metastasis: A case report and literature review.
Ge X; Yang Y; Wang W; Tian L; Zhang G; Tian Z; Xue X
Oncol Lett; 2024 Feb; 27(2):48. PubMed ID: 38192660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
